Founded in 2013, Emulate is a Boston-based company developing organ-on-a-chip systems for various research and drug discovery purposes. By now, they raised a total $224.3M from multiple investors, with the last $82M Series E round led by Northpond Ventures.
Emulate has multiple organ-on-a-chips in their portfolio, specializing on a deeper understanding of the organ function itself, rather than the complex interplay of multiple organs. With the chips for kidney, liver, lung, brain and more, the company claims to effectively predict toxicology profiles or inflammatory responses for the patients. For example, the brain chip contains 5 cell types, forming the human neuro-vascular unit model, which is representative for the blood-brain barrier, cell microenvironment and multicellular diversity.